Connecticut Wealth Management’s TG Therapeutics TGTX Stock Holding History

Connecticut Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,782	Closed	-$259K	–	348
2026 Q1	$259K	Hold	7,782	–	–	0.01%	292
2025 Q4	$232K	Hold	7,782	–	–	0.01%	300
2025 Q3	$281K	Hold	7,782	–	–	0.01%	280
2025 Q2	$280K	Hold	7,782	–	–	0.01%	265
2025 Q1	$307K	Sell	7,782 -7,000	-47%	-$236K	0.02%	255
2024 Q4	$445K	Sell	14,782 -13,000	-47%	-$373K	0.02%	197
2024 Q3	$650K	Hold	27,782	–	–	0.03%	193
2024 Q2	$494K	Hold	27,782	–	–	0.03%	214
2024 Q1	$423K	Hold	27,782	–	–	0.02%	232
2023 Q4	$475K	Hold	27,782	–	–	0.03%	217
2023 Q3	$232K	Hold	27,782	–	–	0.02%	265
2023 Q2	$690K	Hold	27,782	–	–	0.05%	123
2023 Q1	$418K	Hold	27,782	–	–	0.03%	154
2022 Q4	$329K	Hold	27,782	–	–	0.03%	149
2022 Q3	$164K	Hold	27,782	–	–	0.02%	188
2022 Q2	$118K	Buy	27,782 +7,282	+36%	+$45.5K	0.01%	185
2022 Q1	$195K	Buy	+20,500	New	+$237K	0.01%	188

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Connecticut Wealth Management's TGTX Position: Q2 2026 in Review

Connecticut Wealth Management sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 7,782 shares — an estimated $259K sold.

Connecticut Wealth Management first reported a position in TGTX in Q1 2022 and held it in 17 quarters. The position peaked at $690K in Q2 2023. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Connecticut Wealth Management reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
Connecticut Wealth Management sold 7,782 TG Therapeutics shares in Q2 2026, an estimated $259K.
Connecticut Wealth Management first reported a position in TG Therapeutics in Q1 2022 and held it in 17 quarters.
Connecticut Wealth Management's TG Therapeutics position peaked at $690K in Q2 2023.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Connecticut Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.